Nearly every aspect of an antibody can be modified to enhance its therapeutic potential. This includes antibody humanization, optimizing affinity and function, selecting the appropriate isotype, and advancing the development of bispecific antibodies and antibody-drug conjugates.
Consider the potential of high-throughput screening to identify optimal purification strategies for diverse bispecific antibody formats. By enhancing purification efficiency, high-throughput screening supports the advancement of these promising therapeutic candidates for clinical use.
This webinar explores key principles and best practices for designing successful bispecific antibodies. Dr. Timothy Wood, Ph.D., Senior Scientist at Abzena, discusses intelligent bispecific design, emphasizing factors like avidity, spacing, and the configuration of Fab and scFv arms.
The purpose of this study was to evaluate a platform for optimal bispecific design and selection. Key learnings from this project include the importance of gaining high purity from simple purifications and the potential problems with reformatting.
The targeted manipulation of protein structure and function has become an essential step in the early discovery phase. Accurate protein engineering at this stage minimizes the need for costly redesigns and process optimizations later in development.
